文献速递儿科影像泌尿生殖技术与安全MR

儿童MRI钆对比剂:肾脏安全性、风险缓解与新兴替代方案

Gadolinium-based contrast agents in pediatric MRI: renal safety, risk mitigation, and emerging alternatives.
PubMed 文献 · Pediatr Radiol · 2026-04-07

本文综述儿童MRI中钆对比剂(GBCA)的分子结构、儿童特异性药代动力学及不良效应谱,重点讨论肾源性系统性纤维化(NSF)风险。提出风险缓解策略:识别高风险儿童、eGFR<30 mL/min/1.73 m2或疑肾损伤时避免I组和III组制剂、减少终身累积暴露,并概述ferumoxytol等替代对比剂的作用。

要点

  • 儿童使用GBCA前需评估肾功能,eGFR<30 mL/min/1.73 m2或疑肾损伤时避免I组和III组制剂。
  • 减少GBCA终身累积暴露是降低钆沉积和NSF风险的重要策略。
  • 新生儿及有过敏样反应史的儿童需特殊管理,ferumoxytol等替代对比剂作用渐增。

诊断标准与关键数值

  • eGFR<30 mL/min/1.73 m2或怀疑肾损伤时,应避免使用I组和III组GBCA。
  • 需识别儿童中NSF高风险个体并减少GBCA终身累积暴露量。

临床应用与阅片要点

  • 增强MRI前应评估患儿肾功能,eGFR<30 mL/min/1.73 m2或疑肾损伤时避免I组和III组GBCA。
  • 优先选择低风险GBCA并记录累积剂量,减少终身暴露。
  • 新生儿及有过敏样反应史的儿童需个体化评估与预防策略。
  • 关注ferumoxytol等替代对比剂在儿童中的潜在应用。

局限性

  • 本文为综述,未报告系统检索策略与纳入文献数量。
  • 强调儿童特异性研究仍不足,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Gadolinium-based contrast agents (GBCAs) are integral to pediatric magnetic resonance imaging (MRI), yet their use requires thoughtful consideration due to developmental differences in renal function, concerns about gadolinium retention, and the rare but serious risk of nephrogenic systemic sclerosis (NSF). This review summarizes current knowledge on GBCA molecular structure, pediatric-specific pharmacokinetics, and the spectrum of known adverse effects. We discuss practical, evidence-based strategies for risk mitigation, including identifying children at increased risk, avoiding group I and III agents when eGFR is <30 mL/min/1.73 m2 or kidney injury is suspected, minimizing cumulative lifetime exposure, and managing special populations such as neonates and children with prior allergic-like reactions. The review also outlines the growing role of alternative contrast agents, particularly ferumoxytol. By synthesizing current evidence and guideline recommendations, this article provides a comprehensive framework to support safe, effective, and judicious contrast-enhanced MRI in children while emphasizing areas where further pediatric-specific research is needed.

来源:Pediatr Radiol,查看原文。版权归原作者所有。

引用

  1. Jones MM, Boakye AA, Dave N, et al. Gadolinium-based contrast agents in pediatric MRI: renal safety, risk mitigation, and emerging alternatives. Pediatr Radiol. 2026. PMID: 41944845. doi:10.1007/s00247-026-06584-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。